TL;DR
This study reveals that an inflammatory microenvironment, particularly driven by macrophages, is present in Ewing's Sarcoma Family of Tumours (ESFTs), a rare pediatric cancer. Crucially, high expression of the complement protein C5 at the tumor site is linked to significantly better patient survival, suggesting C5 as a potential prognostic marker and therapeutic target.
What Problem Does This Paper Address?
While chronic inflammation is a known precursor to many adult cancers, its role in pediatric neoplasms like Ewing's Sarcoma Family of Tumours (ESFTs) is less understood. ESFTs are typically considered non-inflammatory in origin, and previous research has shown a lack of correlation between inflammatory markers like COX-2 and patient outcomes in these cancers. This paper aims to investigate whether immune system-related genes are activated in ESFTs and if they hold prognostic significance, bridging the gap in understanding the immune microenvironment's role in pediatric cancer development and progression.
Methods
The researchers employed a multi-pronged approach:
- Gene Expression Profiling: They analyzed gene expression data from 44 ESFT patient samples, 11 ESFT cell lines, and 18 normal skeletal muscle samples using Affymetrix microarrays.
- Differential Expression Analysis: They used t-tests and fold-change analysis to identify genes that were significantly up- or down-regulated in ESFT patient samples compared to cell lines and normal muscle tissue. This was done for pre-defined lists of 238 inflammation-related genes and 299 macrophage-related genes.
- Survival Analysis: Kaplan-Meier and Log Rank methods were used to correlate the expression levels of identified genes with patient outcomes (event-free survival and overall survival).
- Immunohistochemistry: To validate gene expression findings at the protein level, they performed immunohistochemical staining for C5 and its receptor C5aR1 on an independent ESFT tumor tissue microarray.
Datasets
- ESFT Patient Samples: Gene expression data from 44 ESFT patients.
- ESFT Cell Lines: Gene expression data from 11 ESFT cell lines.
- Normal Skeletal Muscle Tissue: Gene expression data from 18 normal skeletal muscle samples.
- Independent ESFT Tissue Microarray: Used for immunohistochemical validation.
The study utilized publicly available datasets (GEO accession number GSE17679 for ESFT samples and cell lines, GSE6798 and GSE3526 for normal muscle tissue) and a previously established macrophage gene signature from the SymAtlas database.
Key Insights and Ideas
- Inflammatory Microenvironment in ESFT: Contrary to the notion of ESFTs being non-inflammatory, the study found significant activation of inflammatory genes, particularly those associated with macrophages, within ESFT tumor samples. This suggests that even in pediatric cancers not typically linked to inflammation, an immune component plays a role.
- Macrophages as Key Players: The enrichment of macrophage-related gene expression points to these immune cells as significant contributors to the ESFT tumor microenvironment. This aligns with previous observations of macrophages being the predominant infiltrating immune cells in pediatric solid tumors.
- C5 as a Favorable Prognostic Marker: The most striking finding is the strong correlation between high expression of Complement Component 5 (C5) at the tumor site and superior event-free and overall survival in ESFT patients. This suggests C5 might be actively involved in a protective mechanism or that its presence indicates a more favorable tumor biology.
- C5 and C5aR1 Expression in ESFT Cells: The validation through immunohistochemistry confirmed that C5 and its receptor C5aR1 are expressed not only by infiltrating immune cells but also by the malignant ESFT cells themselves, hinting at potential autocrine signaling loops.
- JAK1 and IL8 as Prognostic Indicators: High expression of JAK1 was also associated with favorable overall survival, while high expression of IL8 correlated with reduced survival, further highlighting the complex interplay of inflammatory mediators in ESFT prognosis.
Key Results
- Inflammatory Gene Upregulation: 16% of inflammatory genes (38 out of 238) were significantly upregulated in ESFT patient samples compared to cell lines (P < 0.001).
- Macrophage Gene Upregulation: 19% of macrophage-related genes (58 out of 299) were significantly upregulated in ESFT patient samples compared to cell lines (P < 0.001).
- C5 and Survival: High expression of C5 was significantly associated with better event-free survival (P = 0.01) and overall survival (P = 0.004) in a dose-dependent manner.
- JAK1 and Survival: High expression of JAK1 correlated with favorable overall survival (P = 0.04).
- IL8 and Survival: High expression of IL8 correlated with reduced overall survival (P = 0.043) in classical Ewing sarcoma.
- Protein Validation: C5 protein expression was detected in 50% of ESFT tumor samples, and C5aR1 expression in 56%, with both primarily localized to malignant cells.
Limitations and Future Work
- Causality vs. Correlation: While strong correlations were found, the study primarily establishes associations. The exact causal role of C5 in improving survival remains to be elucidated.
- Autocrine Loop Investigation: The co-expression of C5 and C5aR1 in ESFT cells suggests an autocrine loop, which warrants further investigation into the downstream signaling pathways triggered by C5 activation.
- Drug Target Potential: The identification of C5 as a prognostic marker opens avenues for exploring its therapeutic potential. Further research is needed to understand how C5 activation influences tumor progression and whether targeting C5 or its pathway could be a viable treatment strategy.
- Broader Tumor Types: The findings on C5's prognostic role are specific to ESFT. Further studies could explore if similar associations exist in other cancer types.
Summary updated